Pancreatic Cancer Research

ResearcherTongji HospitalNo recent work listed

Li Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6875-9396; OpenAlex author ID A5100756915. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper

Papers 10

  1. OPA Interacting Protein 5 Antisense RNA 1 Expedites Cell Migration and Invasion Through FOXM1/ Wnt/β-Catenin Pathway in Pancreatic Cancer. Co-author DOI 10.1007/s10620-021-06919-1↗
  2. Long Noncoding Competing Endogenous RNA Networks in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.765216↗
  3. Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cell… Co-author DOI 10.7150/ijbs.49514↗
  4. MiR-146b-3p regulates proliferation of pancreatic cancer cells with stem cell-like properties by targeting MAP3K10. Co-author DOI 10.7150/jca.48418↗
  5. Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s12943-020-01249-8↗
  6. Danthron suppresses autophagy and sensitizes pancreatic cancer cells to doxorubicin. Last author DOI 10.1016/j.tiv.2018.10.019↗
  7. TFEB-driven autophagy potentiates TGF-β induced migration in pancreatic cancer cells. Co-author DOI 10.1186/s13046-019-1343-4↗
  8. SOCS3 methylation in synergy with Reg3A overexpression promotes cell growth in pancreatic cancer. Co-author DOI 10.1007/s00109-014-1184-8↗
  9. MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3. First author DOI 10.1007/s13277-014-2271-8↗
  10. Balanced Tiam1-rac1 and RhoA drives proliferation and invasion of pancreatic cancer cells. Co-author DOI 10.1158/1541-7786.mcr-12-0632↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Wang · 9 shared papers, 2013–2022 · strength 0.88
  2. Renyi Qin · 7 shared papers, 2013–2022 · strength 0.76
  3. Ruizhi He · 5 shared papers, 2019–2021 · strength 0.49
  4. Xingjun Guo · 5 shared papers, 2013–2021 · strength 0.43
  5. Chengjian Shi · 3 shared papers, 2020–2022 · strength 0.36
  6. Shutao Pan · 3 shared papers, 2019–2021 · strength 0.32
  7. Min Zhou · 3 shared papers, 2019–2021 · strength 0.31
  8. Yuhui Liu · 3 shared papers, 2019–2021 · strength 0.29
  9. Chunle Zhao · 3 shared papers, 2019–2021 · strength 0.29
  10. Xiuhui Shi · 2 shared papers, 2019–2021 · strength 0.20
  11. Jianxin Jiang · 3 shared papers, 2013–2020 · strength 0.16
  12. Yan Zhao · 2 shared papers, 2019–2020 · strength 0.16
  13. Guangbing Xiong · 1 shared paper, 2021 · strength 0.12
  14. Jikuan Jin · 1 shared paper, 2021 · strength 0.12
  15. Min Zhou · 1 shared paper, 2021 · strength 0.12
  16. Hua Chen · 1 shared paper, 2019 · strength 0.09
  17. Jun Gong · 1 shared paper, 2020 · strength 0.08
  18. Shuo Yu · 1 shared paper, 2020 · strength 0.08
  19. Xiaodong Xu · 1 shared paper, 2020 · strength 0.08
  20. Min Li · 1 shared paper, 2020 · strength 0.08
  21. Renyi Qin · 1 shared paper, 2019 · strength 0.08
  22. Hua Chen · 1 shared paper, 2019 · strength 0.08
  23. Yahong Yu · 1 shared paper, 2019 · strength 0.08
  24. Zhipeng Li · 1 shared paper, 2014 · strength 0.04
  25. Chengyi Sun · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.